Exploring New Paradigms in Thrombosis

Anticoagulant use has been critical in thrombosis management; however, currently available agents are often underprescribed, underdosed, and associated with poor compliance, leading to suboptimal patient outcomes. Emerging evidence suggests that factor XI is a promising new target for the inhibition of pathological thrombosis. Join us for this live social media event and interact with Drs Harrington, Mehran, and Barnes as they answer key questions on thrombosis management and share their thoughts on the emerging role of factor XI inhibition.
- - - -
Moderator: Robert A Harrington, MD
Faculty: Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC
Faculty: Geoffrey D. Barnes, MD, MSc
- - - -
Earn free 0.50 AMA PRA Category 1 Credit™. Access for credit will be shared at the end of this live event.
Click the link to view the Accreditation and Disclosure details before participating: Medscape.org/viewarticle/1001951 (this link will be available Monday, November 25).
Supported by an independent educational grant from Bristol Myers Squibb and
Johnson & Johnson Innovative Medicine Alliance.